{"id":1968,"date":"2026-10-01T03:16:48","date_gmt":"2026-10-01T03:16:48","guid":{"rendered":"https:\/\/chatscopeai.com\/news\/united-states-requires-medicare-drug-rebates-tied-to-foreign-prices\/"},"modified":"2026-10-01T03:19:32","modified_gmt":"2026-10-01T03:19:32","slug":"united-states-requires-medicare-drug-rebates-tied-to-foreign-prices","status":"publish","type":"post","link":"https:\/\/chatscopeai.com\/news\/united-states-requires-medicare-drug-rebates-tied-to-foreign-prices\/","title":{"rendered":"United States Requires Medicare Drug Rebates Tied to Foreign Prices from 2027"},"content":{"rendered":"\n<p class=\"wp-block-paragraph hsn-lede\">United States drugmakers must pay Medicare rebates when certain Part B drug prices exceed an international benchmark under the GLOBE Model, which launches Jan. 1, 2027.<\/p>\n<p class=\"wp-block-paragraph\">The Centers for Medicare &amp; Medicaid Services (CMS), the U.S. agency that runs Medicare, on Sept. 30, 2026 finalized a mandatory model requiring makers of certain Medicare Part B drugs to pay rebates benchmarked to foreign prices, starting Jan. 1, 2027<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\" id=\"hsn-cite-1\">1<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The rules behind the model, called the Global Benchmark for Efficient Drug Pricing (GLOBE) Model, take effect on Nov. 30, 2026<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\" id=\"hsn-cite-2\">2<\/a><\/sup>. The final rule is scheduled for publication in the Federal Register on Oct. 2, 2026<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">In short, drugmakers selling certain high-spending, clinic-administered drugs to Medicare will owe extra rebates if their prices sit above what comparable countries pay. Patients in selected areas will pay less coinsurance, and doctors and hospitals will keep billing as usual.<\/p>\n<h2 class=\"wp-block-heading\">What does the GLOBE Model change?<\/h2>\n<p class=\"wp-block-paragraph\">Part B covers drugs that clinicians usually give in health care settings, such as hospitals and doctors&#8217; offices<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. Since the Inflation Reduction Act of 2022, drugmakers already pay Medicare a rebate when they raise prices for certain Part B drugs faster than inflation<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. CMS calculates and invoices those rebates<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">GLOBE tests a different way to calculate that rebate for selected drugs. Instead of a domestic benchmark, CMS will use a benchmark drawn from prices paid in economically comparable countries<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\" id=\"hsn-cite-3\">3<\/a><\/sup>. When the Medicare price for a model drug exceeds that benchmark, the manufacturer pays a rebate into a Medicare trust fund<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The GLOBE rebate will never be less than the rebate owed under the existing inflation rebate program<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. CMS will invoice it using a step-by-step, or incremental, approach<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. The model rests on section 1115A of the Social Security Act, which lets the CMS Innovation Center test new payment models<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">Which countries set the Medicare price benchmark?<\/h2>\n<p class=\"wp-block-paragraph\">The benchmark will come from one of two sources. One is international net pricing data that manufacturers report themselves. The other is pricing data from commercial data providers<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">The reference countries are<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>:<\/p>\n<ul>\n<li>Australia, Austria, Belgium, Canada and the Czech Republic<\/li>\n<li>Denmark, France, Germany, Ireland and Israel<\/li>\n<li>Italy, Japan, the Netherlands, Norway and South Korea<\/li>\n<li>Spain, Sweden, Switzerland and the United Kingdom<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">That is 19 countries in all. CMS cites research from the Department of Health and Human Services finding that U.S. prices for brand-name drugs exceed the average in other developed countries by 422%<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. A separate analysis of the top 50 Part B drugs found U.S. prices averaged 211% higher than in comparable countries<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">Which drugmakers must take part?<\/h2>\n<p class=\"wp-block-paragraph\">Participation is mandatory for all manufacturers of Part B drugs that meet the model&#8217;s eligibility rules and are not excluded<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>. Drugmakers can choose to submit their own international net pricing data, but that submission is voluntary<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">Covered drugs are single-source drugs and sole-source biological products already subject to the Part B inflation rebate program<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. They must fall into one of these drug categories<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>:<\/p>\n<ul>\n<li>antigout agents and cancer drugs (antineoplastics)<\/li>\n<li>blood products and central nervous system agents<\/li>\n<li>immune system drugs and bone disease drugs<\/li>\n<li>eye drugs (ophthalmic agents)<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">Each drug must also have <strong>Medicare Part B spending above $100 million<\/strong> over a 12-month period<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. CMS describes the targeted fields as oncology, rheumatology, immunology, ophthalmology and endocrinology<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">CMS alone decides which drugs enter or leave the model, and that choice cannot be appealed<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. Rebate amounts also cannot be appealed. Manufacturers may only file a <strong>Suggestion of Error<\/strong>, a request to fix a suspected math mistake<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">Which drugs are excluded from the model?<\/h2>\n<p class=\"wp-block-paragraph\">The final rule exempts several groups of products<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>:<\/p>\n<ul>\n<li>drugs with a negotiated maximum fair price under the Medicare Drug Price Negotiation Program<\/li>\n<li>orphan-only drugs, approved only for one or more rare diseases<\/li>\n<li>products on the FDA list of approved cell and gene therapies<\/li>\n<li>plasma-derived products<\/li>\n<\/ul>\n<figure class=\"hsn-fig hsn-fig--solid hsn-fig--v3 hsn-fig--grid2\" data-at=\"which-drugs-are-excluded-from-the-model\">\n  <div class=\"hsn-fig__cards\">\n    <h4>Drugs outside GLOBE<\/h4>\n    <div class=\"hsn-fig__card\" data-series=\"1\">\n      <strong>Negotiated-price drugs<\/strong>\n      <span>Those with a maximum fair price in effect<\/span>\n    <\/div>\n    <div class=\"hsn-fig__card\" data-series=\"1\">\n      <strong>Orphan-only drugs<\/strong>\n      <span>Approved only for rare diseases<\/span>\n    <\/div>\n    <div class=\"hsn-fig__card\" data-series=\"1\">\n      <strong>Cell and gene therapies<\/strong>\n      <span>Products on the FDA list<\/span>\n    <\/div>\n    <div class=\"hsn-fig__card\" data-series=\"1\">\n      <strong>Plasma-derived products<\/strong>\n      <span>Added after public comments<\/span>\n    <\/div>\n  <\/div>\n<\/figure>\n<p class=\"wp-block-paragraph\">Biosimilars, lower-cost copies of biologic drugs, are excluded. So are the original biologics once a biosimilar enters the U.S. market<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. The orphan, plasma and cell and gene therapy exemptions were added after public comments on the proposed rule<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">How will Medicare patients and providers be affected?<\/h2>\n<p class=\"wp-block-paragraph\">The model covers patients in randomly selected ZIP code areas, about 25% of people who have Original Medicare as their primary coverage<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>. People in Medicare Advantage plans or with employer coverage as their main payer are not included<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. CMS picks these patients, and that choice cannot be appealed<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<figure class=\"hsn-fig hsn-fig--solid hsn-fig--v3\" data-at=\"how-will-medicare-patients-and-providers-be-affected\">\n    <div class=\"hsn-fig__cols\">\n    <h4>Who pays on a $100 drug claim, USD<\/h4>\n    <div class=\"hsn-fig__col\" data-series=\"1\">\n      <span class=\"hsn-fig__num\">$90<\/span>\n      <span class=\"hsn-fig__coltrack\"><span class=\"hsn-fig__colfill\" data-v=\"100\"><\/span><\/span>\n      <span class=\"hsn-fig__lab\">Medicare, under GLOBE<\/span>\n    <\/div>\n    <div class=\"hsn-fig__col\" data-series=\"2\">\n      <span class=\"hsn-fig__num\">$80<\/span>\n      <span class=\"hsn-fig__coltrack\"><span class=\"hsn-fig__colfill\" data-v=\"90\"><\/span><\/span>\n      <span class=\"hsn-fig__lab\">Medicare, usual<\/span>\n    <\/div>\n    <div class=\"hsn-fig__col\" data-series=\"3\">\n      <span class=\"hsn-fig__num\">$20<\/span>\n      <span class=\"hsn-fig__coltrack\"><span class=\"hsn-fig__colfill\" data-v=\"20\"><\/span><\/span>\n      <span class=\"hsn-fig__lab\">Patient, usual<\/span>\n    <\/div>\n    <div class=\"hsn-fig__col\" data-series=\"4\">\n      <span class=\"hsn-fig__num\">$10<\/span>\n      <span class=\"hsn-fig__coltrack\"><span class=\"hsn-fig__colfill\" data-v=\"10\"><\/span><\/span>\n      <span class=\"hsn-fig__lab\">Patient, under GLOBE<\/span>\n    <\/div>\n  <\/div><\/figure>\n<p class=\"wp-block-paragraph\">Patients in the selected areas pay lower coinsurance on model drugs. The rule gives an example. On a drug with a $100 allowed amount, coinsurance could fall from 20% to 10%, cutting the patient&#8217;s share from $20 to $10<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. Medicare&#8217;s payment to the provider rises from $80 to $90 in that example<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<p class=\"wp-block-paragraph\">Hospital outpatient departments, physician practices, surgery centers and pharmacies are not model participants<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. They keep buying and billing for the drugs as usual, but must charge the reduced coinsurance when it applies<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading\">When do the GLOBE rebates and lower costs start?<\/h2>\n<p class=\"wp-block-paragraph\">The schedule runs in stages:<\/p>\n<ul>\n<li><strong>Nov. 30, 2026<\/strong>: the regulations take effect<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/li>\n<li><strong>Jan. 1, 2027<\/strong>: the model launches with voluntary manufacturer price data submissions<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/li>\n<li><strong>April 1, 2027<\/strong>: five performance years begin and reduced coinsurance applies<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>.<\/li>\n<li><strong>March 31, 2032<\/strong>: the performance years and reduced coinsurance end<sup class=\"hsn-cite\"><a href=\"#hsn-ref-3\">3<\/a><\/sup>.<\/li>\n<li><strong>March 31, 2034<\/strong>: rebate invoicing and reconciliation end<sup class=\"hsn-cite\"><a href=\"#hsn-ref-1\">1<\/a><\/sup>.<\/li>\n<\/ul>\n<figure class=\"hsn-fig hsn-fig--solid hsn-fig--v3\" data-at=\"when-do-the-globe-rebates-and-lower-costs-start\">\n  <div class=\"hsn-fig__table\">\n    <h4>GLOBE Model timetable<\/h4>\n    <div class=\"pcrstb-wrap\"><table>\n      <thead>\n        <tr><th>Date<\/th><th>What happens<\/th><\/tr>\n      <\/thead>\n      <tbody>\n        <tr><th>Nov. 30, 2026<\/th><td>Regulations take effect<\/td><\/tr>\n        <tr><th>Jan. 1, 2027<\/th><td>Model launches; voluntary price data submissions open<\/td><\/tr>\n        <tr><th>April 1, 2027<\/th><td>Performance years and reduced coinsurance begin<\/td><\/tr>\n        <tr><th>March 31, 2032<\/th><td>Performance years and reduced coinsurance end<\/td><\/tr>\n        <tr><th>March 31, 2034<\/th><td>Rebate invoicing and reconciliation end<\/td><\/tr>\n      <\/tbody>\n    <\/table><\/div>\n  <\/div>\n<\/figure>\n<p class=\"wp-block-paragraph\">CMS will calculate, invoice, collect and reconcile rebates over a 7-year payment period that starts April 1, 2027<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>. For drugmakers, the first concrete milestone is Jan. 1, 2027, when the window opens to submit their own international net pricing data<sup class=\"hsn-cite\"><a href=\"#hsn-ref-2\">2<\/a><\/sup>.<\/p>\n<h2 class=\"wp-block-heading hsn-refs-title\">Sources<\/h2>\n<ol class=\"hsn-refs\">\n<li id=\"hsn-ref-1\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-1\" aria-label=\"Back to reference 1 in the text\">\u21a9<\/a> <a href=\"https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-finalizes-new-mandatory-drug-payment-model-deliver-lower-drug-prices-beneficiaries-original\" rel=\"noopener\" target=\"_blank\">CMS Finalizes New Mandatory Drug Payment Model to Deliver Lower Drug Prices for Beneficiaries in Original Medicare Part B | CMS<\/a> <span class=\"hsn-refs__url\">https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-finalizes-new-mandatory-drug-payment-model-deliver-lower-drug-prices-beneficiaries-original<\/span><\/li>\n<li id=\"hsn-ref-2\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-2\" aria-label=\"Back to reference 2 in the text\">\u21a9<\/a> <a href=\"https:\/\/public-inspection.federalregister.gov\/2026-20281.pdf\" rel=\"noopener\" target=\"_blank\">2026-20281.pdf<\/a> <span class=\"hsn-refs__url\">https:\/\/public-inspection.federalregister.gov\/2026-20281.pdf<\/span><\/li>\n<li id=\"hsn-ref-3\"><a class=\"hsn-refs__back\" href=\"#hsn-cite-3\" aria-label=\"Back to reference 3 in the text\">\u21a9<\/a> <a href=\"https:\/\/www.cms.gov\/priorities\/innovation\/innovation-models\/globe\" rel=\"noopener\" target=\"_blank\">GLOBE (Global Benchmark for Efficient Drug Pricing) Model | CMS<\/a> <span class=\"hsn-refs__url\">https:\/\/www.cms.gov\/priorities\/innovation\/innovation-models\/globe<\/span><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"<p>United States drugmakers must pay Medicare rebates when certain Part B drug prices exceed an international benchmark under the GLOBE Model, which\u2026<\/p>\n","protected":false},"author":1,"featured_media":1966,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","_regnews_id":"35586","_hsn_citations":"[{\"n\":1,\"url\":\"https:\/\/www.cms.gov\/newsroom\/press-releases\/cms-finalizes-new-mandatory-drug-payment-model-deliver-lower-drug-prices-beneficiaries-original\",\"label\":\"CMS Finalizes New Mandatory Drug Payment Model to Deliver Lower Drug Prices for Beneficiaries in Original Medicare Part B | CMS\"},{\"n\":2,\"url\":\"https:\/\/public-inspection.federalregister.gov\/2026-20281.pdf\",\"label\":\"2026-20281.pdf\"},{\"n\":3,\"url\":\"https:\/\/www.cms.gov\/priorities\/innovation\/innovation-models\/globe\",\"label\":\"GLOBE (Global Benchmark for Efficient Drug Pricing) Model | CMS\"}]","_hsn_no_sources":"","_hsn_content_hash":"da28478674cfb46ff1751e471cb7facfd69b74da:913d9f2c382b2e4b2a1013a74138cb7384e066af","_yoast_wpseo_focuskw":"medicare part b drugs","footnotes":""},"categories":[58,40],"tags":[50],"class_list":["post-1968","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-americas","category-pharma-medical","tag-united-states-of-america"],"_links":{"self":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts\/1968","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/comments?post=1968"}],"version-history":[{"count":1,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts\/1968\/revisions"}],"predecessor-version":[{"id":1970,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/posts\/1968\/revisions\/1970"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/media\/1966"}],"wp:attachment":[{"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/media?parent=1968"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/categories?post=1968"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/chatscopeai.com\/news\/wp-json\/wp\/v2\/tags?post=1968"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}